- Active not recruitingPHASE3
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
This study is for people with a specific type of brain tumour called Grade 2 glioma, which has come back or wasn't fully removed by surgery. It's testing a new drug called vorasidenib against a dummy pill to see if it can help stop the tumour from growing.
For: Grade 2 Glioma · Residual Glioma · Recurrent GliomaUnited States · Canada · France - Active not recruitingPHASE1, PHASE2
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
This study looks at a new drug, Vorasidenib, with a standard cancer drug, Temozolomide (TMZ), for a type of brain tumour called glioma. It aims to check if this combination is safe and how well it works.
For: IDH1-mutant Glioma · IDH2-mutant GliomaUnited States · Austria · China - RecruitingPHASE3
Vorasidenib Maintenance for IDH Mutant Astrocytoma
This study is testing a new drug, vorasidenib, for people with a specific type of brain tumour called IDH-mutant astrocytoma. It aims to see if vorasidenib can help stop the tumour from growing back after initial treatment.
For: IDH-mutant Grade 2 or 3 AstrocytomaAustria · Belgium · Czechia